BioVaxys Technology (TSE:BIOV) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
BioVaxys Technology Corp has secured a 48-kilogram supply of GMP-grade lipids to advance the production of its DPX-based vaccines, anticipating a significant ramp-up in preclinical and clinical programs. This acquisition is expected to save the company over a year in manufacturing lead time. BioVaxys continues to innovate with its patented DPX platform, aiming to deliver robust immune responses for various medical applications.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
